Last reviewed 2026-04-23 · How we verify

HGP0608

HGP0608 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.

HGP0608 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects. Used for Muscle wasting or sarcopenia, Bone health / osteoporosis.

At a glance

Mechanism of action

SARMs like HGP0608 are designed to selectively activate androgen receptors in muscle and bone tissue, promoting anabolism and strength gains with reduced impact on prostate and other androgen-sensitive tissues compared to traditional androgens. This selectivity is achieved through tissue-specific receptor modulation and differential coactivator recruitment.

Approved indications

• Muscle wasting or sarcopenia
• Bone health / osteoporosis

Common side effects

• Testosterone suppression
• Liver enzyme elevation
• Headache

Key clinical trials

• A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension (PHASE2)
• A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia (PHASE3)
• A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects. (PHASE1)
• A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects. (PHASE1)
• Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia (PHASE3)
• Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.